No connection

Search Results

LUCD vs MENS

LUCD
Lucid Diagnostics Inc.
BEARISH
Price
$1.28
Market Cap
$218.1M
Sector
Healthcare
AI Confidence
95%
MENS
Jyong Biotech Ltd.
BEARISH
Price
$2.79
Market Cap
$212.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
LUCD
--
MENS
--
Forward P/E
LUCD
-7.11
MENS
--
P/B Ratio
LUCD
-3.87
MENS
-8.91
P/S Ratio
LUCD
46.34
MENS
--
EV/EBITDA
LUCD
-5.38
MENS
-121.13

Profitability

Gross Margin
LUCD
-41.73%
MENS
0.0%
Operating Margin
LUCD
-931.58%
MENS
0.0%
Profit Margin
LUCD
0.0%
MENS
0.0%
ROE
LUCD
-710.6%
MENS
--
ROA
LUCD
-87.2%
MENS
-5.44%

Growth

Revenue Growth
LUCD
25.6%
MENS
--
Earnings Growth
LUCD
--
MENS
--

Financial Health

Debt/Equity
LUCD
2.36
MENS
--
Current Ratio
LUCD
1.31
MENS
0.62
Quick Ratio
LUCD
1.27
MENS
0.62

Dividends

Dividend Yield
LUCD
--
MENS
--
Payout Ratio
LUCD
0.0%
MENS
0.0%

AI Verdict

LUCD BEARISH

LUCD exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness in profitability, leverage, and operating efficiency. The company suffers from catastrophic operating margins (-931.58%) and negative shareholder equity (P/B of -3.87), suggesting a precarious balance sheet. While revenue growth remains positive at 25.6%, there is a massive disconnect between the fundamental decay and the 'Strong Buy' analyst consensus. The valuation is unjustifiable on a data-driven basis, with a Price/Sales ratio of 46.34 for a company consistently missing earnings estimates.

Strengths
Consistent year-over-year revenue growth of 25.60%
Current ratio of 1.31 provides a minimal short-term liquidity buffer
Strong analyst target price ($4.10) suggesting high speculative potential
Risks
Negative book value (P/B -3.87) indicating liabilities exceed assets
Extreme operating losses with an operating margin of -931.58%
Severe financial health deterioration (Piotroski 1/9)
MENS BEARISH

MENS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a critical lack of fundamental value. The company reports a negative Price-to-Book ratio of -8.91, indicating negative shareholders' equity, and a Current Ratio of 0.62, signaling an immediate liquidity crisis. With zero reported revenue and a catastrophic 95% price decline over the last six months, the stock appears to be in a speculative death spiral. Recent short-term gains are likely volatility-driven 'dead cat bounces' rather than a fundamental recovery.

Strengths
Recent short-term price recovery (+40.9% in 1 month)
Small market cap allows for high volatility spikes
Operates in the high-growth Healthcare/Biotech sector
Risks
Negative book value indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.62)
Complete absence of revenue and profit margins

Compare Another Pair

LUCD vs MENS: Head-to-Head Comparison

This page compares Lucid Diagnostics Inc. (LUCD) and Jyong Biotech Ltd. (MENS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile